Gary Singer, MD
Nephrology · Saint Peters, MONPI 1366439283
Payments from drug & device makers
Across 375 payments — averaging $1547.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$464K
- Vifor Pharma, Inc.$73K
- Boehringer Ingelheim$17K
- Bayer$16K
- Fresenius USA Marketing, Inc.$3K
- Quanta Dialysis Technologies Inc$2K
- plus $4K from 31 others
What the payments were for
- Consulting fees$22,12013%
- Speaking & faculty fees$126,37574%
- Grants$5,0003%
- Travel & lodging$6,5324%
- Food & beverage$9,5786%
- Education$980%
- Entertainment$1990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 118 | $464,263 |
| Vifor Pharma, Inc. | 100 | $73,247 |
| Boehringer Ingelheim | 11 | $16,551 |
| Bayer | 16 | $16,393 |
| Fresenius USA Marketing, Inc. | 14 | $3,422 |
| Quanta Dialysis Technologies Inc | 2 | $2,199 |
| Boehringer Ingelheim International GmbH | 7 | $675 |
| Amgen(2 entities) | 26 | $497 |
| Johnson & Johnson | 2 | $390 |
| Travere Therapeutics, Inc. | 12 | $372 |
| Novartis | 12 | $293 |
| Akebia Therapeutics Inc | 9 | $287 |
| Nxstage Medical, Inc. | 3 | $265 |
| Novo Nordisk | 7 | $152 |
| Apellis Pharmaceuticals, Inc. | 1 | $139 |
| Medtronic | 1 | $134 |
| Astrazeneca UK Limited | 1 | $130 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Vantive US Healthcare LLC | 1 | $117 |
| Genentech USA, Inc. | 1 | $91 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Calliditas Therapeutics US Inc. | 2 | $66 |
| GSK | 3 | $63 |
| Covidien LP | 3 | $58 |
| Shire North American Group Inc | 3 | $47 |
| Ardelyx, Inc. | 2 | $44 |
| Mallinckrodt Enterprises LLC | 2 | $41 |
| Cormedix Inc. | 1 | $29 |
| OPKO Pharmaceuticals, LLC | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$58,024
- FARXIGA$50,113
- Kerendia$16,150
- LOKELMA$10,812
- Korsuva$3,121
- INVOKANA$375
- NXSTAGE SYSTEM ONE$333
- SC+ Hemodialysis Machine$199
- SYMPLICITY G3$134
- INJECTAFER$125
- AURYXIA$123
- Vafseo$123
- Renal - PD$117
- LIBERTY SELECT CYCLER$112
How this compares
$580,350 in reported general payments places this provider in the 95th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 121 | $105,439 |
| VelphoroSucroferric Oxyhydroxide | 15 | $53,007 |
| JardianceEmpagliflozin | 49 | $28,439 |
| KerendiaFinerenone | 14 | $15,353 |
| EliquisApixaban | 11 | $10,527 |
| Sevelamer Carbonate | 34 | $7,440 |
| ProsolParenteral Amino Acid 20% No.1 | 21 | $3,649 |
| Calcium Acetate | 16 | $1,441 |
| Torsemide | 79 | $1,363 |
| Losartan Potassium | 158 | $1,262 |
| Midodrine Hcl | 21 | $1,258 |
| Telmisartan | 15 | $714 |
| Furosemide | 130 | $646 |
| Doxazosin Mesylate | 39 | $556 |
| Carvedilol | 43 | $496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $464,263 | $105,439121 claims |
| Fresenius USA Marketing, Inc.Velphoro | $3,422 | $53,00715 claims |
| Boehringer IngelheimJardiance | $16,551 | $28,43949 claims |
| BayerKerendia | $16,393 | $15,35314 claims |
| PfizerEliquis | $15 | $10,52711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 253 nephrology providers in Missouri.
Other nephrology in Saint Peters
- Ahmed AwadKansas City$12.4M
- Benjamin HumphreysSaint Louis$1.2M
- Donovan PolackFlorissant$782K
- Derek LarsonCreve Coeur$605K
- Daniel CoyneSaint Louis$563K
- Tarek AlhamadSaint Louis$477K
- Tingting LiSaint Louis$370K
- Anuja JavaSaint Louis$365K
- Marcos RothsteinSaint Louis$350K
- Ying ChenSaint Louis$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.